



News Release

Suven Revenue up by 49.21%; PAT up by 83.23% for the Fourth quarter ended March 2016

HYDERABAD, INDIA (27 May' 2016) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specialized in CRAMS for global life science companies and drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 31st March 2016. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 27th May' 2016 at Hyderabad.

Financial Highlights for the 4th Quarter ended March' 2016 (QoQ):

Growth in income INR 1738 Mn vs 1165 Mn - up by 49%

Growth in PAT INR 323 Mn vs 177 Mn - up by 82%

Growth in EBIDTA INR 474 Mn vs 286 Mn - up by 66%

Financial Highlights for the year ended March' 2016:

Growth in income INR 5189 Mn vs 5294 Mn - down by 2%

Growth in PAT INR 950 Mn vs. 1088 Mn - down by 13%

Growth in EBIDTA INR 1426 Mn vs 1680 Mn - down by 15%

Suven's expenses on innovative R&D in Drug Discovery stood at INR 630 Mn (12% on revenue) for the year ended Mar' 2016.

On consolidation of the accounts of Suven, Inc., USA, the wholly owned subsidiary, the PAT reduced to INR 667 Mn and expenditure on R&D increased to INR 911 Mn.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;